LP
EWTX icon

Longaeva Partners’s Edgewise Therapeutics EWTX Stock Holding History

Longaeva Partners’s Portfolio EWTX Stock Details EWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.16M Buy
+36,931
New +$1.06M 0.04% 168

Other funds holding EWTX

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Longaeva Partners's EWTX Position: Q1 2026 in Review

Longaeva Partners opened a new position in Edgewise Therapeutics (EWTX) in Q1 2026: 36,931 shares worth $1.16M. The stake represents 0.04% of the portfolio and ranks #168 among its holdings.

214 funds tracked by Wall St. Rank hold EWTX as of Q1 2026.

  • Longaeva Partners held 36,931 shares of Edgewise Therapeutics worth $1.16M as of Q1 2026.
  • Edgewise Therapeutics was a new Longaeva Partners position in Q1 2026.
  • Edgewise Therapeutics made up 0.04% of Longaeva Partners's portfolio in Q1 2026, its #168 holding.
  • 214 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q1 2026.

Based on Longaeva Partners's 13F filing for Q1 2026, filed 15 May 2026.